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A response to
Commentary: A hypothesis for examining skeletal muscle biopsy-derived sarcolemmal nNOSµ 
as surrogate for enteric nNOSα function
by Percival J. Front Med (2015) 2:70. doi:10.3389/fmed.2015.00070
Accommodation of food/liquid bolus or chyme/chyle within the esophagogastrointestinal lumen 
necessitates relaxation of the muscular wall (1–3). This relaxation is mediated by two neurotransmit-
ters released in tandem from the nerve terminals that are in microscale proximity to the smooth 
muscles. Sequential evoked release of soluble purine derivatives, notably ATP and de novo synthe-
sized gaseous nitric oxide (NO) relaxes the smooth muscles (4, 5). The mechanical relaxation is 
preceded by an electrical event, the inhibitory junction potential (IJP), which is the sine qua non of 
enteric musculomotor inhibitory neurotransmission (6–8).1 Regional movement also necessitates 
contraction of the smooth muscles mediated by cholinergic muscarinic stimulation but throughout 
the gastrointestinal tract, “inhibitory neurotransmission-mediated accommodation” is the single 
most important functional component that allows oro-aboral accommodation and progression 
of gut contents (9). Not surprisingly, the disorders pertaining to gastrointestinal motility mainly 
results from defects in accommodation, chiefly due to impairment of inhibitory neurotransmission 
(1, 10–12).
Importantly, the dual cascade of inhibitory neurotransmission posits a fascinating cell biology 
challenge. While the purine derivatives, including ATP, are released from membrane-delimited 
vesicles, nitric oxide (NO) is synthesized de novo, meaning that synthesis is instantaneously coupled 
to an incoming action potential at the nerve terminal1 (1). ATP-mediated fast IJP and NO-mediated 
slow IJP are coupled to each other in time, and this has been demonstrated by several labs over the 
decades and mires in no controversy. Theoretically, it may seem that nitric oxide may be synthesized 
1 http://www.nature.com/nature/report/index.html?comment=59974&doi=10.1038/464466a
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by nNOS anywhere within the cell provided it has the right 
molecular arrangement, namely, a dimeric state and stimulus 
for electron flow for oxidation of l-arginine. However, surpris-
ingly, in both neuronal and non-neuronal cells, nNOS appears 
to be located to specific cellular microdomains for activity. 
These microdomains are mainly localized at the cell membrane 
(13–15). Though detailed experiments to address the rationale of 
these cellular organizations are lacking, it is likely that the major 
purpose for specific microdomain localization of nNOS at the 
membrane may necessitate from the need to molecularly interact 
with calcium channels and other regulators of its activity (for 
example, specific kinases and phosphatases) (1). These allosteric 
mechanisms can only occur if macromolecular complexes are 
in enough nanoscale proximity within the cell. Here, it may be 
emphasized that the membrane-localized nNOS is possibly not 
the only site of nNOS presence. In almost all cells in which nNOS 
are present, staining for nNOS is diffusely seen within the cell. 
In the enteric nerve terminals, nNOS, despite its presence in the 
cytosol, does not actively synthesize NO. This is mainly because 
of its phosphorylated status, which renders it inactive for nitric 
oxide biosynthesis (15–17). However, particulate fraction of 
nNOS is the main active form has been demonstrated by different 
methodologies for nNOS distribution, including within enteric 
nerve terminals and skeletal muscles (18–26).
Herein belies the major significance of examining membrane-
bound nNOS to test the efficiency of nitrergic neurotransmis-
sion. Despite scant attempts to obtain full-thickness intestinal 
biopsies, largely, this is not a common practice for the sheer 
challenge of perforating the gut. Thus, obtaining information 
from biomarkers is a major diagnostic issue and of paramount 
importance to the field of neurogastroenterology. In most gas-
trointestinal motility disorders, functional evidence of failure of 
relaxation is obtained indirectly by imaging and manometry (2, 
11, 12). Preclinical studies reveal deficits of nitrergic function 
both in disorders involving the proximal and distal gut. However, 
an important dilemma arises while examining pathological 
specimens obtained from GI motility disorders. In these biop-
sies, nNOS staining appears normal, including in the enteric 
nerve terminals. These observations create confusion in clin-
icopathological diagnosis. A recent study has demonstrated that 
in diabetes mellitus, nNOS synthesis and distribution remain 
relatively unaffected, whereas myosin Va genomic expression is 
severely impaired, with virtual absence in the nerve terminals 
(27). Earlier, we had demonstrated the critical role of myosin Va 
in transport of nNOS in the enteric nerve terminals, possibly by 
interacting with LC8, the light chain of dynein (also called PIN, 
protein inhibitor of nNOS) (28). These findings may help clarify 
molecular targets for motility disorders, which are currently only 
classified as “idiopathic” or “functional.”
Using an inbred strain of mouse that lacks myosin Va, the 
dilute DBA/2J mice, we have additionally demonstrated that 
cavernosal nitrergic neurotransmission is impaired in deficiency 
of myosin Va (29). The major isoform that mediates nitrergic 
neurotransmission in the penile cavernosal nerve terminals is not 
nNOSα but rather nNOSμ (30), the same splice variant present 
in skeletal muscles. This study provided evidence of binding of 
nNOS and myosin Va in cavernosal extracts (29). Based on this 
background information, I presented my opinion that imaging 
and subcellular examination of skeletal muscle biopsies may 
potentially provide information on nNOS cellular localization 
within the enteric nerve terminal (31).
Though I am being repetitive, I shall elaborate why my 
opinion is rationally derived. Skeletal muscle contains nNOSμ, a 
closely related splice variant to nNOSα (32). Several groups have 
described the presence of nNOSμ and, in fact, highlighted that 
activity of nNOS is comparable in skeletal muscles than in the 
brain, despite tissue-specific differential translation. In a classical 
experiment, Lainé and de Montellano demonstrated that addition 
of nNOSμ to brain supernatant or pellet results in same levels 
of NO production as addition of nNOSα (33). The reciprocal 
experiment, addition of nNOSα to the leg muscle supernatant or 
pellet also yielded similar results to those obtained by addition of 
nNOSμ. These experiments could not discern differential tissue 
effects on the catalytic rates of the two isoforms (33). Thus, despite 
measurable differences (34), nNOSμ and α are very closely related 
to each other, not only molecularly but also in their catalytic 
properties. The subtle electronic properties may contribute to 
region-specific needs, but currently the basis is far from known. 
Most importantly, there can be no denial that most nNOS in skel-
etal muscles is clustered and confined to the space just below the 
cell membrane (32). This is a striking light microscopic appear-
ance whenever one visualizes a skeletal muscle section stained 
for nNOS. Diffuse staining is seen throughout the sarcoplasm 
but is always much lighter in intensity. Thus, the nNOSμ at the 
cell membrane stands out in sharp contrast to nNOSμ diffusely 
spread within the cell cytoplasm. NADPH diaphorase examina-
tion reveals staining at the sarcoplasm, again suggesting that 
the nitric oxide synthesis is mainly confined to the periphery in 
skeletal muscles. In my perspective (31), I pointed out that this 
simple imaging observation may serve as a preliminary surrogate 
assay to examine the efficiency of cell membrane localization of 
nNOS in general and nNOSα in particular.
I never interpreted, neither posited, that nNOSμ is solely 
located at the cell membrane (31). There are important subcel-
lular localizations of nNOS within the cytoplasm (26, 32, 35), 
with nNOSβ predominantly distributed in the cytoplasm and 
have been shown to be in association with Golgi complex (36). 
The discussion of nNOSβ is beyond the scope of this response, 
but I may briefly mention that even on this aspect, there is an 
intriguing similarity between the skeletal muscle and the enteric 
prejunctional nerve terminal. In the enteric terminal, nNOSβ is 
concentrated in the cytosol and remains phosphorylated; in con-
trast, however, to skeletal muscle, nNOSβser847P does not produce 
NO when stimulated in vitro (16, 17). Interestingly, similar obser-
vation for nNOSβ has been recently reported in cardiomyocytes; 
nNOSβ are phosphorylated and remain in association with the 
cardiomyocyte cytoskeleton within the cytosol (37), similar to 
skeletal muscles (36). nNOSβ has the full enzymatic capacity to 
support oxido-reduction to generate NO but lacks the N terminal 
specialized domains to associate with membrane (31, 36). In 
skeletal muscles, nNOSβ may associate with dystrophins (36, 
38). It merits further investigation whether availability of nNOSβ 
may be dependent on membrane localization to the subcellular 
organelle or can function in free-floating form, and what special 
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adaptations it may need under such circumstances. Increasing 
evidence shows that NO biosynthesis may not be stochastic but 
rather rely on specific cellular microdomain(s) localization in 
order to have a functional allosteric relation (e.g., association 
with calcium channels on the ER or plasma membrane). In the 
general commentary, the author provides an erroneous reference 
of the role of cytoplasmic nNOS in the maintenance of RyR of 
endoplasmic reticulum (39). However, the study referenced is an 
in vitro study and does not specifically examine the contribution 
of membrane or cytoplasmic nNOS (39), and it merits specific 
techniques to knockout membrane-bound nNOS and thereafter 
assesses the role of nNOS localized elsewhere in the cell and its 
specific impact on physiological functions. There are other splice 
variants similar to nNOSβ, for example, the testicular nNOS 
(TnnNOS), which shows a highly interesting molecular property 
(40). In built into its structure is the LC8 domain, which may 
aid in its localization to specific cellular domain. Further studies 
may help reveal the specific roles of nNOSβ in enteric nerves 
and skeletal muscles, including whether they act as a reserve 
when nNOSα does not function properly within the enteric or 
cavernosal nerves (35), as in chronic conditions such as diabetes 
mellitus, or the specific role of nNOS splice variants on genomic 
expression of local growth factors and impact on local or systemic 
organs (41–45).
Based on these observations, I hypothesized that in gastro-
intestinal motility disorders, including in idiopathic disorders, 
membrane-bound nNOS in sarcolemma may be reduced or 
deficient, as the intracellular transport mechanisms may be 
similar for nNOS in diverse cells and may depend on LC8/PIN 
and actin-interacting myosins, including myosin Va (1, 31). This 
was based on the assumption that myosin Va defect may be a 
major component of the motility disorders and could be distrib-
uted pathophysiological event. This was based on the common 
pathognomonic feature from available evidence that nNOS 
staining/expression and distribution in enteric nerve terminals 
remains relatively unaffected (including some reports mention-
ing increase in nNOS expression) in several motility disorders 
(46, 47), despite consistent observations of impaired nitric oxide 
synthesis in physiological experiments (27). Thus, skeletal muscle 
nNOS may be tested to obtain valuable information about differ-
ent aspects of nNOS within enteric nerve terminals based on the 
following similarities:
 (i) Genomic synthesis mechanisms and expression status. 
Though alternate splicing mechanisms contribute to the 
differential expression of nNOSμ and α (48), μ isoform is 
not exclusively present in skeletal muscles. For example, 
cavernosal nerves and several brain regions contain μ (30, 
49). Similarly, though nNOSμ is the major transcript, some 
studies have suggested that nNOSα may also be present in 
skeletal muscles (50). This important point needs further 
validation. A very interesting aspect regarding nNOSμ and 
α transcriptional/translational similarity is demonstrated by 
the fact that in nNOSα knockout mice, nNOSμ is absent in 
skeletal muscles (36, 51). The nNOSα mice show prominent 
gastrointestinal symptoms, including notable gastroparesis 
on a solid diet (52) (Figure 1). This may severely affect their 
nutrition, thus contributing to the observed low muscle 
weight (36, 51). Using double knockout involving both 
nNOSα and β, preliminary studies have suggested lack of 
force development post-mild exercise regimens, and this 
has been attributed to the function of beta splice variant 
(36). This study also makes the important suggestion that 
sustained NO provides important feedback physiological 
impact to the skeletal muscle myofilaments (36). However, 
additional studies are needed to decipher the contributing 
role of NO synthesized by nNOSμ at the periphery, as well as 
novel models such as nNOSα + nNOSβ− mice to study the 
role of nNOSβ in mediating this function of force generation 
after a cycle of contraction–relaxation. In nNOSα knockout 
animals (36, 52), nNOSα may be absent in regions of skeletal 
NMJs and may impact postsynaptic acetylcholine receptor 
clustering. This may have important impact on force genera-
tion in the skeletal muscles, apart from chronic ischemia due 
to nNOSμ deficiency at the sarcolemma. Skeletal muscles 
may be useful for testing nNOSα/β stoichiometry and any 
commonality or differences in relation to their distribution 
in enteric nerve terminals. The suggested biopsies (31) may 
also provide important information regarding the regula-
tion of nNOS transcription/translation and participatory 
genome regulatory elements for nitrergic biosynthesis and 
its allosteric modulators.
 (ii) Mechanism of intracellular transport to the site of active 
nitrergic synthesis. The pools exchange. In the skeletal mus-
cle, the nucleus is located in the periphery. Thus, after nNOS 
transcript synthesis, nNOSμ/α/β mRNA must be trans-
ported out of the nucleus and thence to the ER and Golgi for 
functional secretion back to the cytoplasm. A major portion 
of this pool gets actively localized to the sub-sarcolemmal 
region. Myosin Va may transport nNOSμ. Myosin Va has been 
shown to be present in skeletal muscles (31). Furthermore, it 
has been suggested that PIN/LC8, the adaptor of nNOS for 
myosin Va (27, 28, 31), is upregulated in skeletal muscles and 
is localized to the periphery in the sub-sarcolemmal region 
in Duchenne dystrophy (55). Despite the lack of dystrophin 
or nNOSmembrane in these muscles, upregulation of PIN likely 
results from compensatory mechanism due to lack of nNOS, 
suggestive of a role of PIN/LC8 in transport of nNOS to the 
peripheral sub-sarcolemmal region in skeletal muscles (55). 
The docking/clustering mechanisms for nNOS in the sub-
membranous zone of the cell periphery are different in the 
skeletal muscles and in the enteric nerve terminals. Unlike 
the misrepresentation in the general commentary (56), I 
never posited that the membrane loose-adhesion mecha-
nisms are same (31)! In the enteric nerve terminals, which 
are prejunctional in its anatomic localization, PSD95 tethers 
nNOS to the membrane (15), much like the postsynaptic 
cells of the central nervous system. The proteins involved are 
different in skeletal muscles and comprise macromolecular 
complexes of syntrophins, dystrophin, dystrobrevin, and 
sarcoglycans (32). However, there may be a lot of heterogene-
ity in these aspects. First of all, these anchoring mechanisms 
have been only limitedly studied in the ENS. Furthermore, 
many skeletal muscles may not have the complete repertoire 
FIGUre 1 | Sarcolemmal nnoS may be dislocated from membrane in a variety of diseases and may not necessarily be associated with immobility. 
(a) In contrast to controls, induction of myasthenia gravis result in cytosolic dislocation of nNOS mu. Note loss of sarcolemmal distribution of nNOS in mdx mice, a 
model for Duchenne muscular dystrophy. Skeletal muscle contains nNOS in different pools, including (i) sarcolemma, (ii) subcellular membranous organelles, (iii) 
free-floating, (iv) mitochondria, (v) neuromuscular junctions (which is neurophysiologically a fast-conducting synapse, unlike enteric nerve terminal-smooth muscle 
junctions), and (vi) intrafusal and extrafusal fibers. These different pools are potentially separable by fractionation techniques and complexly interact to impact 
skeletal muscle mechanical and metabolic actions. (B) Skeletal muscle contractile status may not necessarily be correlated with membrane-located sarcolemmal 
nNOS. Hypotonic muscles show lack or presence of sarcolemmal nNOS, depending on mobility status. These observations merit further detailed history and 
case-by-case analyses. (C) Left panel shows absence of nNOSμ in skeletal muscle extracts in nNOS knockout mice, in comparison to wild-type littermates. This 
critical observation shows that deletion of exons for nNOSα transcription/translation possesses the necessary molecular capacity to knockout nNOSμ from skeletal 
muscles. The middle panel shows prominent gastroparesis in nNOS knockout mice. Defective nutrition may potentially impact body weight and skeletal muscle 
mass and function. The right panel shows fluoroscopic appearance of nNOS knockout mice. Note its small body size in comparison to wild-type littermates.  
(D) Comparative observation from a small-scale study of human skeletal muscle biopsies showing that sarcolemmal nNOS distribution may not have any significant 
correlation with subject mobility status. Note that in nearly one-third of subjects with normal mobility, sarcolemmal nNOS may be defectively localized; additionally, 
subjects with impaired mobility may have normal sarcolemmal nNOS [reproduced with permission from Baum et al. (51), Mashimo et al. (52), Finanger Hedderick 
et al. (53), and Meinen et al. (54)].
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and yet function, for example, chicken and turtle muscles 
do not have sarcoglycan (whereas, sarcoglycan deficiency 
causes major disease in humans) (57). Dystrophins and 
syntrophins may also be present in the CNS neurons (58). It 
is being gradually appreciated that in the face of molecular 
crowding (59), be it in the skeletal muscle or the enteric 
nerve terminals, precise chemical docking mechanisms due 
to molecular homologies of protein interactions potentially 
lead to precision in cellular streaming and localization and 
function, despite the spatial cytosolic molecular entropy (1, 
60). This also contributes to a dynamic pool, exchanging 
nNOS between the membrane and cytosol with respect 
to specific physiological demands (1, 16, 32). Though the 
impact of pharmacological treatment is virtually unknown, 
one preclinical study has demonstrated that the gene 
expression of myosin Va is enhanced upon treatment of 
mdx mice with prednisolone (61). Thus, the comparative 
examinations of the splice variants acquire great significance. 
Interestingly, a recent proteomic study has demonstrated 
that in  prednisolone-induced skeletal muscle myopathy, 
associated with membrane nNOS mislocalization, several 
classes of myosin heavy chains are upregulated, including 
Myh1, Myh2, Myh4, and Myh11 (62). This could likely be a 
compensatory mechanism to the loss of sarcolemmal nNOS, 
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and the role of specific cortical myosins and its impact on 
nitrergic biosynthesis is only gradually being appreciated.
 (iii) nNOSμ at the sarcolemma dislocates in skeletal muscle dis-
eases, as well as systemic diseases in which gastrointestinal 
motility impairment manifest and may not necessarily be 
associated with induction of skeletal atrophy. In several 
primary skeletal muscle diseases, including Duchenne 
dystrophy, nNOSμ dislocates (32). This is an established 
finding. The sub-sarcolemmal dislocation leading to dif-
fuse cytosolic staining are seen not only when membrane 
clustering mechanisms are deficient but also in myopathies, 
experimentally induced myasthenia, as well as in metabolic 
disease like diabesity (31, 32, 55, 62, 63). Given the role of NO 
in modulation of acetylcholine receptors (54, 64) (Figure 1) 
as well as the critical function of glucose uptake and insulin 
receptor functioning in the skeletal muscles (65, 66), it is 
reasonable to hypothesize that cytosolic transport of nNOSμ 
to the membrane is of tremendous significance and merits 
detailed examination. There may be some GI disorders, for 
example, cirrhosis-associated sarcopenia, which may result 
in chronic wasting and muscle fatigue, nNOSμ unloading 
and upregulation of autophagy (67), similar to muscle 
disease in COPD (68) or other disorders, such as critical ill-
ness myopathy, multiple sclerosis, cancer cachexia, chronic 
kidney disease, or cardiac cachexia (53, 54, 69, 70), but I had 
not focused on these polyvariable conditions in my earlier 
perspective (31). My main aim of the discussion remained 
whether we may find additional evidence of idiopathic 
motility disorders by examining skeletal muscle nNOS 
expression and distribution, given the practical difficulties 
of obtaining whole-thickness gut biopsies. In fact, not all 
skeletal muscle disorders in which nNOSμ are dislocated 
from the membrane generates an autophagic or atrogin/
MuRF response. A recent study incorporating 164 skeletal 
muscle biopsies from different cohorts of patients, includ-
ing skeletomuscular disorders, have shown that in nearly 
one-third of subjects, there is sub-sarcolemmal dislocation 
of nNOS but apparently without any neuromuscular prob-
lems (53, 62) (Figure 1). nNOSμ may be dislocated during 
spaceflight or microgravity simulation, but does it toggle 
between membrane and cytosolic location during relative 
periods of inactivity and hypotonia like sleep? Sarcolemmal 
nNOS is a common phenomenon observed across species 
(71). Similarly, it shall be interesting to examine the effects 
of physiological inactivity like hibernation and torpor on 
sarcolemmal nNOS distribution and recovery, or in sub-
clinical conditions like chronic statin use, hypothyroidism, 
and HIV infection prior to development of frank cachexia. 
In general, nNOS localized to the membrane is protected 
from calpain-mediated autolysis (33, 72, 73); however, the 
precise mechanisms of timing of half-life of nNOS with 
respect to its cellular location are far from known, but 
definitely is another important area for exploration. Precise 
impact of functional gastrointestinal disorders (FGIDs) like 
irritable bowel syndrome (IBS) on nutrition and skeletal 
muscle mass has not been examined in details. However, 
even if muscle atrophy responses are evoked, these are 
important aspects to consider, as it may contribute to insulin 
resistance and cascadic effect on normal gastric emptying, 
as well as important implications for fatigue, workplace 
performance, and disability compensation. These aspects 
merit careful observations, studies, and inferences. Some 
of the alternative interpretations raised in the critique (56) 
may be important while studying aging populations, with 
concomitant ongoing sarcopenia and chronic constipation 
and risk of development of diverticulosis. Interestingly, a 
recent study has demonstrated that myalgic muscle fibers 
show dislocated nNOSμ from the sarcolemma but could 
recover by exercise (74). Whether exercise in general has 
a positive impact on genomic expression of nNOS and its 
allosteric regulators are significant and feasible therapeutic 
avenues to explore.
There are numerous diseases of the upper esophagus and 
esophageal body that coexist with skeletal muscle neuromuscular 
diseases (75). Skeletal muscle disorders can also pose important 
gastrointestinal motility problems; for example, significant 
prejunctional vesicular defects as well as smooth muscle atrophy 
is seen in gut of mdx animal model of Duchenne muscular dys-
trophy (76, 77). These studies, including my own scant investiga-
tions, are in its infancy but definitely warrant aggressive testing 
at a pilot scale. Skeletal muscle fatigue is a very complex topic 
and multifactorial in origin. In diabetes, it may potentially result 
from myosin Va defect, or even from a primary myosin heavy 
chain defect. It is well-known that diabetes causes significant bio-
chemical dysfunction of myosin heavy chain isoforms, including 
in skeletal muscles and cardiomyocytes (78, 79). Frankly, I could 
not comprehend the unreferenced and non-chalant correlation of 
gastrointestinal motility disorders with patient immobility (56)! 
Functional GI disorders are a huge clinical problem worldwide, 
including in the United States (80). The subjects are in distress: 
think of someone needing to visit the restroom several times a 
day, with either diarrhea or an incomplete evacuation, or a child 
with cyclical vomiting, with episodes several times a day. There 
is a significant loss of physical quality of life, important impact 
on nutritional status, and loss of workplace efficiency. And, these 
disorders are not uncommon! Probe an acquaintance with an 
empathetic ear, and one shall soon hear a story! Most importantly, 
only scant information is known regarding the pathophysiol-
ogy of these disorders. For this cohort of patients, who run in 
millions only within the United States (79), one very important 
aspect is to provide an answer to “what is my problem?” Most 
physicians would not endeavor to logically approach and do the 
complex work up, and often these subjects end up in psychiatric 
consultations or try alternate methods of medicine. A sort of 
closure is provided if a logical diagnostic work up is offered. 
The progression of contents through the gut is a neuromuscular 
phenomenon, and examining the nerve terminals or the smooth 
muscles, along with other cellular elements in the neuropil is of 
paramount importance (31). Despite my personal experience 
with patients with functional motility disorders for nearly two 
decades, I have never encountered a single presentation where the 
subject is incapacitated primarily due to the motility disorder. Of 
course, someone after a bout of diarrhea or an episode of vomiting 
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may have felt weak, or an elderly person may have been frail, or 
someone with abdominal pain may have been confined to bed 
for a few hours, but I have not seen a direct association between 
long-term GI motility disorder and skeletal muscle fatigue, unless 
there has been a primary disorder like association of dysphagia 
in amyotrophic lateral sclerosis. It is interesting and significant 
that the development of fatigue, for example, in diabetes mel-
litus, is stochastic, and again, not all skeletal muscles behave in 
the same way. For example, if my thesis holds well, it still cannot 
provide a reductionist view of why, despite potential deficiencies 
of myosin(s) function, we do not commonly encounter diabetes 
with progressive respiratory failure due to diaphragmatic paraly-
sis (81)! These subtle differences of pathophysiology surely shall 
lead us into next steps of translational investigations.
Pools of nNOS are in dynamic relation between the membrane 
and the cytosol, be it in skeletal muscle, cardiomyocyte, or the 
prejunctional enteric nerve terminal. However, a snapshot of 
nNOS expression and distribution in skeletal muscles may still 
be very useful information. A subject could be pursued to pro-
vide two samples, at rest and after a period of moderate physical 
activity in order to examine any potential differences (though 
developing a protocol for obtaining two biopsies may in itself be 
a logistic IRB challenge). Furthermore, a wide pool of datasets 
shall take care of variance, just like in any other experimental 
setup. Thus, Dr. Percival’s discounting my suggested approaches 
as “uninformative” (56) is unreliant on critical inferences of 
the testable hypothesis and not taking into consideration the 
published evidence related to the differential aspects of nNOS 
cellular distribution and pathobiology. There are only a few labs 
worldwide that focus on the molecular medicine of complex GI 
motility disorders. These investigations should be vigorously pur-
sued as an indefatigable advocacy for motility disorder patients 
who rightfully may demand to know what exactly the basis of 
their disease is. As I think through, nNOSμ is present not only 
in skeletal muscles but also in cardiomyocytes and cavernosal 
neurons (30, 37). Thus, examining skeletal muscle nNOSμ may 
not only provide evidence for nNOS synthesis/intracellular trans-
port/localization/activity in the enteric nerve terminals but also 
provide additional evidence for erectile dysfunction and cardio-
myopathy arising from defective nNOSμ signaling in the penile 
cavernosa and heart. I welcome Dr. Percival’s probing comment 
(56) who is an expert in the field of nNOSμ in skeletal muscles and 
invite him to join my endeavors for delivering all things possible 
to the care of these subjects with recalcitrant disorders that cause 
enormous suffering. In my opinion, therein lies the true spirit of 
translational investigations and precision medicine.
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